In a groundbreaking advancement in metabolic research, scientists have uncovered a promising pathway to combat obesity without compromising bone health in male mice. This discovery pivots on the manipulation of sulfur amino acid metabolism, specifically focusing on glutathione depletion through a compound known as D, L-buthionine-(S, R)-sulfoximine (BSO). The findings herald new potential for targeted anti-obesity therapeutics, circumventing the skeletal side effects typically associated with dietary sulfur amino acid restriction (SAAR).
SAAR, characterized by a diet low in methionine and devoid of cysteine, has been well-documented for its powerful anti-obesity effects. However, these benefits come at a cost—long-term SAAR induces significant reductions in bone mineral density (BMD), compromises bone microarchitecture, and elevates marrow adiposity. The complex interplay between sulfur amino acid metabolism, redox homeostasis, and skeletal integrity has presented challenges in developing strategies that harness the metabolic advantages of SAAR without incurring deleterious bone outcomes.
The latest study, conducted by researchers at the Orentreich Foundation for the Advancement of Science and led by Dr. Naidu B. Ommi with correspondence by Dr. Sailendra N. Nichenametla, delves into these mechanistic intricacies by employing BSO. This glutathione synthesis inhibitor acts to reduce intracellular glutathione levels, mimicking a key downstream effect of SAAR. The team’s objective was to investigate whether BSO could replicate the anti-obesity phenotype of SAAR while sparing bone tissue from the associated damage.
Using high-fat diet-induced obese male C57BL6/NTac mice, the researchers designed an experimental paradigm comparing four groups: a control methionine-sufficient diet, a SAAR diet, SAAR supplemented with the glutathione precursor N-acetylcysteine (NAC), and control diet supplemented with BSO in the drinking water. This comprehensive design allowed for the dissection of the effects attributable directly to sulfur amino acid deprivation versus glutathione depletion.
Sophisticated assessments including in vivo body composition analysis, micro-computed tomography (micro-CT), histomorphometric quantification, and biomechanical testing painted a comprehensive picture of metabolic and skeletal phenotypes. As anticipated, mice on the SAAR diet exhibited marked reductions in total and visceral fat mass, confirming the diet’s potent anti-obesity capabilities. Concomitantly, however, these mice demonstrated significant declines in trabecular and cortical BMD, reductions in osteoblast numbers, increases in marrow adiposity, and decreased mechanical strength in bone structures.
Intriguingly, supplementation with NAC effectively reversed the detrimental bone changes induced by SAAR, restoring BMD and osteoblast counts, and normalizing marrow adipose tissue volumes. This reversal emphasizes the pivotal role of cysteine and glutathione availability in maintaining bone homeostasis under conditions of sulfur amino acid restriction.
The most salient finding emerged from the group receiving BSO alongside a methionine-replete diet. Despite profound glutathione depletion—comparable to that induced by SAAR—these mice exhibited the characteristic lean phenotype with reduced fat mass, mirroring the anti-obesity effects of SAAR. Strikingly, however, BSO administration did not replicate the bone phenotypes seen with SAAR; bone mineral density remained intact, osteoblast numbers were preserved, marrow adiposity did not increase, and biomechanical properties of bones were unaffected.
This divergence reveals a decoupling of the pathways controlling fat loss and bone metabolism in the context of glutathione depletion and sulfur amino acid availability. The data suggest that while glutathione lowering via BSO drives metabolic benefits, the concomitant cysteine deficiency inherent to SAAR is critical for bone deterioration. The protective effect of NAC further corroborates this, pointing to cysteine/glutathione biosynthesis as essential for bone health maintenance.
Beyond the metabolic and skeletal readouts, the study employed osmium tetroxide staining and micro-CT imaging to evaluate marrow adiposity in distinct tibial regions. These advanced imaging modalities confirmed that while marrow adipocyte volumes were elevated in SAAR groups, BSO had no measurable effect on marrow fat content. This nuanced spatial analysis supports a model where marrow adipogenesis is specifically sensitive to sulfur amino acid deprivation rather than exclusively to glutathione depletion.
While this study establishes BSO as a novel pharmacological tool for dissecting the complex biochemistry of sulfur amino acid metabolism, the authors emphasize the imperative for further research. Mechanistic studies are needed to elucidate the molecular underpinnings by which glutathione manipulation selectively influences adiposity without compromising bone. Moreover, investigations addressing potential age-dependent responses, sex-specific effects, and long-term safety profiles are critical prerequisites before considering translational applications.
The significance of these findings extends into therapeutic realms, where safe, targeted anti-obesity interventions remain an unmet need. Current pharmacotherapies often suffer from adverse effects or limited efficacy, particularly in preserving skeletal integrity—a crucial aspect for aging populations vulnerable to osteoporosis. The paradigm presented by the BSO-mediated separation of metabolic and skeletal pathways offers a promising avenue to develop treatments that mitigate obesity without exacerbating bone fragility.
This research also prompts reconsideration of sulfur amino acid dietary recommendations and their systemic impacts beyond energy metabolism. The delineation of cysteine and glutathione’s divergent roles could inspire precision nutritional interventions that optimize metabolic health while safeguarding the musculoskeletal system.
In conclusion, the study of D, L-buthionine-(S, R)-sulfoximine in recapitulating the anti-obesity effects of sulfur amino acid restriction without bone loss marks a pivotal contribution to metabolic and skeletal biology. By disentangling the dual pathways influencing fat reduction and bone homeostasis, this work opens novel investigative and therapeutic horizons. As the global obesity epidemic persists, innovations that reconcile efficacy with safety are paramount, positioning this research at the forefront of metabolic science.
Subject of Research: Animals
Article Title: D, L-Buthionine-(S, R)-sulfoximine recapitulates the anti-obesity effects of sulfur amino acid restriction without the associated deleterious effects on bone in male mice
News Publication Date: March 2, 2026
Web References: https://doi.org/10.18632/aging.206358
Image Credits: Copyright © 2026 Ommi et al., Creative Commons Attribution License (CC BY 4.0)
Keywords: Bone, Aging, Methionine, Glutathione, Redox
Tags: bone mineral density preservation strategiesDeffects of methionine and cysteine restrictionglutathione depletion and metabolic healthglutathione synthesis inhibition benefitsL-buthionine sulfoximine (BSO) mechanismmale mice obesity and bone healthmarrow adiposity in dietary interventionsmetabolic research in obesity treatmentredox homeostasis and skeletal integritysulfur amino acid metabolism in obesitysulfur amino acid restriction anti-obesity effectstargeted anti-obesity therapeutics development
